Breach
Moderna stock crashes 25%, loses about $24 billion after cancer vaccine data leak
Moderna’s stock price dropped over 25% after trial results for its personalized melanoma vaccine with Merck were disclosed. The decline erased approximately $24 billion from Moderna’s market value, ending a significant rally this year. Analysts noted that thi…
Read at The Times of India↗Headline from NewsAPI.